US EditionDuchenne Myopathy: Genethon Gene Therapy Enters the Final Trial Phase
Summary by La Croix
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
On Friday 25 July, the Genethon laboratory obtained the authorisation of the European Medicines Agency to start the phase III trial of its gene therapy, a decisive step before possible placing on the market in five years' time.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
